Related Experiment Videos
[Current classification of anti-arrhythmia agents]
Insights
Antiarrhythmic drugs are classified by Vaughan Williams classes (I-IV) based on their effects on myocardial targets. Drug choice depends on electrophysiological effects and frequency dependence, crucial for managing arrhythmias and avoiding proarrhythmic risks.
Area of Science:
- Cardiology
- Pharmacology
- Electrophysiology
Background:
- Antiarrhythmic drugs are classified into four Vaughan Williams classes (I-IV) based on their electrophysiological effects on the myocardium.
- These classes target specific myocardial channels: sodium, potassium, and calcium, as well as beta-adrenergic receptors.
- The "Sicilian Gambit" offers a more detailed classification based on drug targets.
Purpose of the Study:
- To emphasize that selecting antiarrhythmic drugs requires understanding their electrophysiological effects.
- To highlight the critical role of frequency dependence in determining antiarrhythmic and proarrhythmic properties.
- To differentiate subclasses of Class I and Class III antiarrhythmics based on their specific mechanisms and rate-dependent behaviors.
Main Methods:
- Analysis of the Vaughan Williams classification and the "Sicilian Gambit" approach.
- Evaluation of the frequency dependence of electrophysiological effects for Class I (sodium-channel blockade) and Class III (potassium-channel blockade) antiarrhythmics.
- Differentiation of Class III drugs based on their inhibition of specific potassium current components (IKr and IKs).
Main Results:
- Class I drug's sodium-channel blockade is rate-dependent, with subclassification based on block-frequency relation.
- Class III drugs inhibiting IKr show reverse rate dependence, potentially causing torsades de pointes at low heart rates.
- Class III drugs inhibiting IKs are under investigation, potentially showing rate-independent effects but with uncertain proarrhythmic risk, as suggested by LQT1 syndrome.
Conclusions:
- Appropriate antiarrhythmic drug selection hinges on understanding electrophysiological effects and rate dependence.
- Understanding specific channel targets (IKr vs. IKs) is crucial for predicting drug behavior and potential proarrhythmic risks.
- Further research is needed for Class III drugs targeting IKs to ascertain their safety profile, especially concerning congenital long QT syndrome.
Abstract:
Antiarrhythmic drugs can be divided into four Vaughan Williams classes (I-IV) according to defined electrophysiological effects on the myocardium. Thus, the Vaughan Williams classification also coincides with the main myocardial targets of the antiarrhythmics, i.e., myocardial sodium-, potassium-, and calcium-channels or beta-adrenergic receptors. A more detailed characterization which is also based on the myocardial targets of a drug is given by the "Sicilian Gambit" approach of classification. Nevertheless, the appropriate drug for the management of a given clinical arrhythmia has to be chosen according to the electrophysiological effects of the respective drug. A main determinant of the antiarrhythmic or proarrhythmic properties of a drug is the frequency dependence of its electrophysiological effects. The sodium-channel blockade induced by class-I substances is enhanced with increasing heart rates. Thus, class-I antiarrhythmics can be subclassified as substances showing a more exponential, an approximately linear, or rather saturated block-frequency relation. Class-III antiarrhythmics (potassium-channel blockade) can be further differentiated according to the component of the delayed rectifier potassium current (IK) which is inhibited by a drug. Class-III drugs inhibiting selectively the rapidly activating and deactivating IKr component exhibit a marked reverse rate dependence, i.e., the drug induced prolongation of the cardiac action potential is minimized at high rates. On the other hand, during bradycardia the pronounced action potential prolongation may cause early afterdepolarizations and triggered activity leading to torsades de pointes arrhythmias (acquired QT syndrome). Class-III substances inhibiting the slowly activating IKs component are currently under investigation and are expected to show a direct rate dependence. Experimental data available so far point to an action potential prolonging effect at least independent of rate. However, it is uncertain whether proarrhythmic effects can be thus avoided, especially in light of the fact that one form of congenital QT syndrome (LQT1) seems to be linked to dysfunction of the IKs-channel.